Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Ankylosing Spondylitis, Gout, Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F

Market Overview

Global Rheumatology Therapeutics Market was valued at USD 26.11 Billion in 2024 and is expected to reach USD 37.05 Billion in the forecast period with a CAGR of 5.98% through 2030. Rheumatology therapeutics refers to the branch of medical science and healthcare focused on the diagnosis and treatment of rheumatic diseases. Rheumatic diseases are a diverse group of conditions that primarily affect the musculoskeletal system, including the joints, muscles, bones, and connective tissues. These diseases can lead to symptoms such as joint pain, stiffness, inflammation, and limited mobility. Rheumatology therapeutics encompasses various medical approaches and treatments aimed at alleviating these symptoms, managing the underlying disease, and improving the quality of life for individuals affected by these conditions. The rising incidence and prevalence of rheumatic diseases, such as rheumatoid arthritis, osteoarthritis, and lupus, were driving the demand for rheumatology therapeutics. Factors such as an aging population and changes in lifestyle contributed to the higher prevalence.

Biologic drugs, including TNF inhibitors, interleukin inhibitors, and JAK inhibitors, continued to be at the forefront of rheumatology therapeutics. Ongoing research and development efforts led to the introduction of new and more effective biologic therapies. The growth of the biosimilar market for rheumatology drugs was a driver, offering cost-effective alternatives to branded biologic drugs. Biosimilars were expanding access to treatment while reducing healthcare costs. Advances in genetics and molecular biology were leading to the development of personalized medicine approaches in rheumatology. Tailoring treatments to individual patients based on their genetic and immune profiles improved treatment outcomes. The COVID-19 pandemic accelerated the adoption of telemedicine in rheumatology, allowing patients to receive remote consultations, monitor their conditions, and access care more conveniently.

Key Market Drivers

Increasing Prevalence of Rheumatic Diseases

Rheumatic diseases, including osteoarthritis, rheumatoid arthritis, and gout, are becoming increasingly prevalent due to several interrelated factors. As the global population ages, the incidence of these conditions naturally rises. In 2019, approximately 528 million people worldwide were living with osteoarthritis, marking a 113% increase since 1990, with about 73% of them over the age of 55. Additionally, obesity, a major risk factor for osteoarthritis and other rheumatic conditions, has been on the rise. In 2022, one in eight people globally were living with obesity, with adult obesity rates more than doubling since 1990. Another contributing factor is modern sedentary lifestyles, which have been linked to the increasing prevalence of joint and musculoskeletal disorders. As of 2022, nearly a third of adults worldwide were insufficiently physically active, exacerbating the risk of developing rheumatic diseases.

Genetic predisposition also plays a critical role, with rheumatoid arthritis heritability estimated at about 60%, influenced by specific genetic markers such as HLA. Environmental factors like pollution have been associated with the onset and exacerbation of these diseases, as studies indicate that air pollution can increase the risk of rheumatoid arthritis. Improved diagnostic methods and growing awareness among healthcare professionals have led to earlier and more accurate diagnoses, with the U.S. reporting that 21.2% of adults (53.2 million) had been diagnosed with arthritis between 2019 and 2021. Many of these conditions are chronic, meaning patients live with them for extended periods, further increasing overall prevalence. Gender disparities also influence rheumatic disease rates, with rheumatoid arthritis being two to three times more common in women than in men. Additionally, rheumatic diseases often coexist with comorbidities such as cardiovascular disease or diabetes, further adding to the healthcare burden. Regional variations in diet, lifestyle, and healthcare access further affect the prevalence of these conditions. These factors collectively highlight the growing demand for effective rheumatology therapeutics, driving advancements in treatment options and healthcare policies globally.

Advancements in Biologic Therapies

​Biologic therapies have transformed the management of autoimmune diseases by specifically targeting molecules or cells involved in the immune response, offering more effective and targeted treatments compared to traditional systemic therapies. These biologics have significantly improved outcomes for conditions such as rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus by addressing the underlying immune dysfunction responsible for these diseases. Many of these therapies are monoclonal antibodies designed to bind to specific proteins like tumor necrosis factor (TNF) or interleukins, thereby reducing inflammation and preventing tissue damage. For instance, TNF inhibitors have demonstrated sustained efficacy and a decreased rate of radiographic progression in patients with early aggressive RA undergoing long-term treatment.​

The advent of biosimilars highly similar alternatives to existing biologic drugs has further enhanced access to these therapies. In the United States, the adoption of biosimilars has led to substantial cost savings. For example, the Department of Veterans Affairs reported saving USD 67 million in 2023 through the adoption of biosimilars for psoriasis treatment . Despite these advancements, challenges remain in achieving widespread adoption, with some biosimilars experiencing adoption rates as low as 13% due to market dynamics. Nonetheless, ongoing research continues to identify new therapeutic targets, expanding treatment options and improving patient outcomes. The integration of personalized medicine approaches, facilitated by advances in genomics and biomarker research, enables clinicians to tailor biologic therapies to individual disease profiles, thereby enhancing treatment effectiveness.

Growing Awareness and Diagnosis

Increased awareness about rheumatic diseases and their symptoms has led to earlier and more accurate diagnoses. Early diagnosis is crucial for effective management and preventing long-term joint damage. Patient advocacy groups, healthcare organizations, and healthcare providers have focused on educating the public about rheumatic diseases. This education helps individuals recognize symptoms and seek medical attention promptly. Some regions have implemented screening and awareness programs for conditions like rheumatoid arthritis, which can lead to earlier intervention and better outcomes. Historically, there has been a delay in diagnosing rheumatic diseases due to their varied and often subtle symptoms. Growing awareness aims to reduce this delay and expedite treatment. Greater awareness has helped change perceptions of rheumatic diseases, which were sometimes dismissed as simply "aches and pains" in the past. Recognizing the seriousness of these conditions has led to increased demand for effective treatments. Public health campaigns, including Arthritis Awareness Month and World Lupus Day, have raised awareness about rheumatic diseases on a global scale.

Advances in medical imaging, blood tests, and biomarker research have improved diagnostic accuracy, making it easier to identify rheumatic diseases. The prevalence of rheumatic diseases is rising, partly due to factors like an aging population and lifestyle changes. This growing patient population naturally drives demand for rheumatology therapeutics. Informed patients are more likely to engage in their healthcare and seek appropriate treatment. This patient empowerment contributes to the demand for therapeutics. Greater awareness has spurred research and the development of new treatments, giving patients hope for better outcomes. Effective rheumatology therapeutics can significantly improve patients' quality of life, reducing pain, disability, and the need for surgical interventions. Rheumatic diseases can have a substantial economic impact due to medical costs and lost productivity. Raising awareness highlights the societal and economic importance of effective treatment. Awareness efforts have helped reduce the stigma associated with rheumatic diseases, encouraging individuals to seek help and treatment. This factor will accelerate the demand of Global Rheumatology Therapeutics Market.

Download Free Sample Report

Key Market Challenges

High Treatment Costs

Many rheumatology medications, particularly biologic drugs, can be extremely expensive. Patients often face high out-of-pocket costs, even with insurance coverage. This financial burden can lead to non-adherence to treatment plans, which can worsen disease outcomes. The high cost of treatment can create disparities in access to care. Patients with limited financial resources may struggle to afford rheumatology therapeutics, potentially leading to delayed diagnosis and inadequate treatment. High treatment costs place a strain on healthcare systems, particularly in countries with publicly funded healthcare. Budget constraints can limit the availability of certain therapies and affect the quality of care provided. The cost of biologic drugs and other rheumatology treatments can contribute to higher health insurance premiums, affecting both individuals and employers providing healthcare coverage. Policymakers and healthcare advocates are increasingly concerned about the affordability of rheumatology therapeutics. This has led to discussions about pricing reforms and measures to improve drug cost transparency. Rheumatic diseases can lead to disability and reduced work productivity. The economic burden of these diseases, combined with high treatment costs, affects individuals' ability to participate in the workforce. High costs can limit treatment options for patients and healthcare providers, leading to challenges in finding cost-effective, yet efficacious, therapies. The introduction of biosimilars (generic versions of biologic drugs) has the potential to reduce the cost of rheumatology therapeutics. However, increasing adoption and acceptance of biosimilars remain challenges.

Drug Safety and Side Effects

Many medications used in rheumatology therapeutics, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic agents, can have side effects. These side effects range from mild to severe and can affect various body systems. Some rheumatology drugs, particularly immunosuppressive medications like DMARDs and biologics, can weaken the immune system. This increases the risk of infections and requires vigilant monitoring. Biologic drugs, while highly effective, can carry specific side effects related to immunosuppression and their mechanism of action. These side effects may include an increased risk of certain infections, injection site reactions, and infusion-related reactions. NSAIDs, commonly used for pain and inflammation, can lead to gastrointestinal side effects, including stomach ulcers and bleeding. Some rheumatology medications, such as certain NSAIDs, have been associated with an increased risk of cardiovascular events. Long-term use of corticosteroids, which are sometimes prescribed for rheumatic diseases, can lead to bone loss and an increased risk of osteoporosis. Some medications can affect blood cell counts, leading to conditions like anemia, leukopenia, or thrombocytopenia. Certain rheumatology drugs may affect liver and kidney function, necessitating regular monitoring. Patients can experience allergic reactions to certain medications, which can range from mild rashes to severe anaphylactic reactions. Some medications may cause mood changes, anxiety, or depression in some individuals.

Key Market Trends

Patient-Centric Care

Rheumatologists and healthcare providers are increasingly engaging patients in shared decision-making. This approach involves discussing treatment options, risks, benefits, and patient preferences to arrive at a mutually agreed-upon treatment plan. Recognizing that rheumatic diseases can vary widely in their presentation and impact, patient-centric care emphasizes tailoring treatment plans to the specific needs of each patient. This may include selecting medications or therapies based on the patient's disease severity, lifestyle, and comorbidities. Informed patients are better equipped to actively participate in their care. Healthcare providers in rheumatology are placing a strong emphasis on educating patients about their conditions, treatment options, and self-management strategies. Patient-centric care also addresses issues of access and affordability. Healthcare providers and institutions work to ensure that patients have access to the treatments they need and that financial barriers are minimized whenever possible. Patients are encouraged to actively participate in monitoring their disease activity and reporting any changes or concerns to their healthcare providers. Regular follow-up appointments and communication are essential components of patient-centric care. Since pain is a common symptom of rheumatic diseases, patient-centric care places a strong focus on pain management strategies tailored to individual patient needs. Rheumatology therapeutics are not just about managing physical symptoms; they also consider the emotional well-being of patients. Addressing the psychological aspects of living with a chronic condition is integral to patient-centric care.

Segmental Insights

Indication Insights

Based on the Indication, Osteoarthritis emerged as the dominant segment in the Global Rheumatology Therapeutics Market in 2024. Osteoarthritis is one of the most common forms of arthritis, and it affects a large portion of the global population, particularly in aging populations. This high prevalence contributes to the significant market share as more patients seek treatment. The global population is aging, and osteoarthritis is more common among older individuals. With the demographic shift towards older age groups in many countries, there's a growing patient population in need of osteoarthritis treatments. Factors like obesity, sedentary lifestyles, and physical trauma are associated with an increased risk of developing osteoarthritis. These lifestyle-related risk factors contribute to the continued prevalence of the condition. Osteoarthritis is a chronic, degenerative condition for which there are no known curative treatments. Therefore, patients often require long-term management with medications and therapies, leading to a sustained market for osteoarthritis therapeutics.

Distribution Channel Insights

Based on the Distribution Channel, Hospital Pharmacies emerged as the dominant segment in the Global Rheumatology Therapeutics Market in 2024. Hospitals often play a central role in the diagnosis and initial treatment of severe or acute rheumatic diseases. Patients with such conditions may receive their initial medications and therapies through hospital pharmacies. Some rheumatic diseases require specialized care and medications, which are typically administered or dispensed within a hospital setting due to the complexity of the treatments. Hospitals provide both inpatient and outpatient services. Patients may receive rheumatology therapeutics during their hospital stay and continue their treatment through the hospital's outpatient pharmacy. Patients with acute rheumatic disease flares or complications may seek emergency care at hospitals, where they can receive immediate treatment through the hospital pharmacy.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Rheumatology Therapeutics Market in 2024. This is due to a combination of advanced healthcare infrastructure, high disease prevalence, and strong market penetration of biologics and biosimilars. The region has a well-established healthcare system with extensive reimbursement policies, allowing patients greater access to innovative rheumatology treatments. Additionally, the rising prevalence of rheumatoid arthritis, psoriatic arthritis, and other autoimmune disorders has driven the demand for effective therapeutics, contributing to market growth. The presence of key pharmaceutical and biotechnology companies, such as AbbVie, Amgen, and Pfizer, has further strengthened the market by fostering continuous research and development in targeted therapies. Regulatory support from agencies like the U.S. Food and Drug Administration (FDA) has facilitated the rapid approval and commercialization of novel biologics and biosimilars, enhancing treatment options.

Asia-Pacific emerged as the fastest growing region in the Global Rheumatology Therapeutics Market during the forecast period. This is due to the increasing burden of rheumatic diseases and improving healthcare infrastructure. The rising prevalence of rheumatoid arthritis, osteoarthritis, and lupus across countries like China, India, and Japan has led to a surge in demand for effective treatment options. Additionally, growing awareness about early diagnosis and disease management has resulted in higher adoption rates of advanced therapies, including biologics and biosimilars. Governments in the region are actively investing in healthcare modernization, leading to improved access to rheumatology treatments. In particular, public and private sector initiatives to expand healthcare coverage have enabled more patients to receive specialized treatment. The expansion of universal health insurance schemes in countries such as China and India has further facilitated market growth by reducing the financial burden on patients seeking long-term treatment for chronic rheumatic conditions.

Recent Developments

• In November 2024, Capstan Therapeutics presented preclinical data on CPTX2309, its lead in vivo CAR-T candidate, at the ACR Convergence 2024 in Washington, D.C. The data support advancing CPTX2309 into clinical trials by mid-2025. Developed through Capstan’s CellSeekern platform, CPTX2309 delivers mRNA encoding an anti-CD19 CAR to reprogram CD8+ cytotoxic T cells, enabling deep B cell depletion without lymphodepletion chemotherapy. This next-generation approach aims to combine the potency of CAR-T therapy with the scalability and predictability of biologics.
• In November 2024, Aurinia Pharmaceuticals Inc. announced the acceptance of four poster presentations at the American College of Rheumatology Convergence (ACR) 2024, held in Washington, D.C., from November 14-19. The data emphasize the need for enhanced lupus nephritis (LN) screening and highlight the clinical significance of LUPKYNIS (voclosporin) in treating active LN. Additionally, a pilot study (NCT05417854) evaluated the SecondWave MINI, a novel wearable ultrasound device for noninvasive treatment of inflammatory disorders, in rheumatoid arthritis. Conducted at the University of Minnesota Medical School and funded by DARPA, the study involved 13 participants receiving splenic ultrasound therapy over eight weeks, assessing safety and initial efficacy.
• In November 2024, Synthekine Inc. announced encouraging preclinical results for its STK-009 + SYNCAR-001 program, a novel engineered cytokine therapy. The regimen demonstrated potential in treating autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) without the need for lymphodepletion. These findings will be presented at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C.
• In November 2024, Exo Therapeutics, Inc., a preclinical-stage biotech firm, presented a late-breaking poster at the American College of Rheumatology’s Convergence Conference in Washington, D.C. The presentation highlighted its preclinical program targeting the TBK1/STING interaction in the cGAS-STING pathway, which is linked to autoimmune diseases like SLE, CLE, SSc, and Sjögren’s. Traditional inhibitors struggle with selectivity, leading to off-target effects. Exo’s novel exosite inhibitors aim to overcome these limitations by selectively disrupting STING-mediated TBK1 activation while preserving its essential roles in viral suppression and autophagy.
• In May 2024, SecondWave Systems, Inc. announced the completion of a pilot clinical study evaluating its noninvasive ultrasound stimulation technology for rheumatoid arthritis (RA). The study, involving 13 participants receiving splenic ultrasound treatment, showed significant disease improvement in 10 patients and positive treatment feedback from all. No serious device-related adverse events were reported. The SecondWave MINI, a wearable therapeutic ultrasound device, was tested in this single-arm study conducted by the University of Minnesota Medical School and funded by DARPA.
• In January 2024, U.S.-based Rise Therapeutics initiated a Phase I clinical trial for R-2487, an oral immunotherapy for rheumatoid arthritis. The study, conducted across multiple U.S. sites, will assess the drug’s safety, pharmacodynamics, and clinical efficacy in up to 36 patients by evaluating disease severity improvements and key biomarkers.

Key Market Players

• AbbVie Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc. 
• Merck & Co., Inc.
• Amgen Inc.
• Novartis AG
• Janssen Pharmaceuticals, Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Johnson & Johnson Private Limited
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Rheumatology Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•  Rheumatology Therapeutics Market, By Indication:

o    Ankylosing Spondylitis

o    Gout

o    Osteoarthritis

o    Psoriatic Arthritis

o    Rheumatoid Arthritis

•  Rheumatology Therapeutics Market, By Distribution Channel:

o    Hospital Pharmacies

o    Retail Pharmacies

o    Online Pharmacies

• Rheumatology Therapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rheumatology Therapeutics Market.

Available Customizations:

Global Rheumatology Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Rheumatology Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com